Grail said to be planning IPO in Hong Kong to raise $500M

Cancer cells image
Cancer detection maker Grail is said to be planning an IPO in Hong Kong to raise $500 million. (Pixabay)

Grail, which seeks to develop liquid biopsies to catch cancer early, is looking at an initial public offering in Hong Kong, Bloomberg reported.

If the IPO comes to fruition, the offering would help bolster the Asian market’s attempts to attract more biotech listings.

Although a final offering amount hasn’t been set, unnamed sources told Bloomberg that Grail may be seeking to raise as much as $500 million. Grail, like Shanghai Henlius Biotech, may be looking to take advantage of the Hong Kong exchange’s proposed new listing rules designed to entice early-stage biotech firms to the market, the news service said.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Grail declined to comment on the report, Bloomberg said.

Late last year, the Menlo Park, California-based company, which is backed by Bill Gates and Jeff Bezos, announced its screening test for a type of cancer commonly found in Asia would be launched in Hong Kong later this year. Other investors in Grail include Tencent Holdings, Bristol-Myers Squibb, Celgene, Johnson & Johnson Innovation and Merck.

Grail spun out of Illumina a little over a year ago, and the company raised $900 million in series B financing by last March. The money, along with $100 million in series A funding previously raised, was directed to support large-scale clinical trials involving hundreds of thousands of patients.

The company is focusing on tracking DNA shed by tumors that circulates in the blood.

Read more on

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

Five years after Congress passed a law to reduce unnecessary MRIs and CT scans, federal officials have yet to implement it.